Lumosa Therapeutics’ LT3001 for stroke receives FDA approval to begin clinical trials
Taipei, Taiwan-headquartered Lumosa Therapeutics Co., Ltd. has announced that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials.
Read more